Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01538680
First received: February 21, 2012
Last updated: June 29, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given